Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Inclusion Criteria:

Any autologous or syngeneic patient who underwent high dose melphalan (>= 140 mg/m^2) therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial which is also evaluating long-term disease free survival or survival
Platelet count (transfusion independent) > 50,000 cells/mm^3 and absolute granulocyte count > 1500 cells/mm^3 for 5 calendar days after recovery from high dose therapy
Patients should be between 30 days to 120 days after transplant
Willingness and ability to comply with Food and Drug Administration (FDA)-mandated REV ASSIST Program, Celgene System for Lenalidomide Education and Prescribing Safety
Signing a written informed consent form

Exclusion Criteria:

Karnofsky score less than 70
A left ventricular ejection fraction less than 45% immediately pre transplant; patients with congestive heart disease with transplant, history of myocardial infarction (MI), or history of coronary artery disease
Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease), serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) > 2.5 x upper limit of normal
Calculated by Cockcroft-Gault formula or measured serum creatinine clearance < 25 ml/minute
Pregnant and/or lactating females
Patients who cannot give informed consent
Patients with untreated systemic infection
Patients with history prior to transplant of treatment with combination therapy Lenalidomide/Biaxin and steroid without response
Patients allergic to lenalidomide, biaxin or dexamethasone
Referring physician not registered with REV ASSIST program or unwilling to oversee the care of the patients on study and comply with the FDA-mandated REV ASSIST Program
Patients unwilling to practice adequate forms of contraception if clinically indicated until 30 days after stopping therapy; male patients on study need to be consulted to use latex condoms (even if they have had a vasectomy) every time they have sex with a woman who is able to have children while they are being treated and for 30 days after stopping drugs
Patients with >= grade 3 peripheral neuropathy
Prior history of uncontrollable side effects to dexamethasone therapy
A prior history of human immunodeficiency virus (HIV) positivity with pre-transplant evaluation